Premium
Reduced‐intensity conditioning followed by T‐cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse
Author(s) -
Ringhoffer Mark,
Harsdorf Stephanie von,
Schmitt Michael,
Wiesneth Markus,
Zenz Thorsten,
Stilgenbauer Stephan,
Greiner Jochen,
Döhner Konstanze,
Marx Martin,
Döhner Hartmut,
Bunjes Donald
Publication year - 2007
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2006.06404.x
Subject(s) - medicine , transplantation , imatinib , chronic myeloid leukaemia , minimal residual disease , oncology , hematology , myeloid , stem cell , gastroenterology , surgery , myeloid leukemia , immunology , leukemia , biology , genetics
Summary A pilot trial was initiated for chronic myeloid leukaemia patients, which employed imatinib for remission induction, followed by reduced‐intensity conditioning and an in vivo T‐cell depleted graft. Out of nine patients, six experienced a molecular relapse and one patient had a haematological relapse at a median interval of 5 months after transplantation. Five relapsing patients achieved a 2nd molecular remission after treatment with either donor lymphocyte infusions ( n = 4) or imatinib ( n = 1). Two of nine patients died due to infectious complications. The probability of survival 2 years after transplant was 74% (95% CI 42–100%).